Test Price
2,800 AED✅ Home Collection Available
CHRND Gene Sequencing for Congenital Myasthenic Syndrome Type 3C | 2800 AED | DHA Licensed Test
Executive Summary & Core Metrics
- 99.9% Analytical Sensitivity – ISO 9001:2015 certified NGS workflow validated against ClinVar and gnomAD databases.
- 3–4 Week TAT – Expedited reporting with genetic counselor review.
- Sample Options: Blood (EDTA/ACD), Extracted DNA, or Dried Blood Spot (FTA Card).
- VIP Mobile Phlebotomy – 8 AM–11 PM, 7 days/week, by DHA-licensed phlebotomists.
- Immediate WhatsApp Support: +971 54 548 8731 – direct billing verification & counseling scheduling.
Test Overview & Methodology
This next‑generation sequencing (NGS) test analyzes the entire coding region of the CHRND gene, the definitive molecular diagnosis for Congenital Myasthenic Syndrome Type 3C with acetylcholine receptor deficiency. Delivered with 99.9% analytical specificity and a dedicated post‑test counseling call, the report empowers neurologists, pediatricians, and clinical geneticists across the UAE to personalize treatment and surveillance.
| Feature | Our CHRND NGS Panel | Closest Alternative (Single‑Gene Sanger) |
|---|---|---|
| Method | Next‑Generation Sequencing (100% coverage) | Sanger sequencing (limited to known hot‑spots) |
| Analytical Sensitivity | >99.9% | ~95% |
| Turnaround Time | 3–4 weeks | 6–8 weeks |
| Post‑Test Counselling | Included (30‑min tele‑consult) | Not included |
Physician Insight & Safety Protocols
“In over a decade of clinical genetics practice, I have witnessed the power of precise molecular diagnosis in congenital myasthenic syndromes. This CHRND gene test is not just a laboratory value; it is the gateway to tailored therapy, prognostication for families, and informed reproductive choices. Always correlate results with clinical phenotype and electrophysiology.”
– Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA License #9294403
Advisory: Medication and Clinical Guidance
Medication Warning
Do not discontinue any prescribed medication (e.g., pyridostigmine, ephedrine, or salbutamol) without consulting your treating physician. Genetic testing complements clinical management; results must be interpreted alongside current therapeutic response.
Patient Safety Exclusion Criteria & Emergency Red Flags
Exclusion Criteria for Home Collection:
- Current acute respiratory distress or impending crisis
- Inability to provide informed consent (obtain legal guardian consent per UAE Federal Decree-Law No. 4 of 2016 for minors)
- Active febrile illness or hemodynamic instability
- Known contraindication to venipuncture (severe bleeding disorder without replacement therapy)
Seek Immediate Emergency Care if:
- Sudden worsening of muscle weakness, especially respiratory muscles
- Difficulty swallowing or choking
- Blurred vision, drooping eyelids, or slurred speech progressing rapidly
- Unexplained falls or apnea episodes in neonates
Patient FAQ & Clinical Guidance
1. What is the accuracy of the CHRND NGS test for diagnosing congenital myasthenic syndrome type 3C?
Our NGS protocol achieves over 99.9% analytical sensitivity and specificity, covering all coding exons and splice sites of the CHRND gene with validated bioinformatics pipelines. This level of precision, combined with ClinVar/gnomAD cross‑referencing, virtually eliminates false‑negative results seen with older single‑gene tests.
2. Can I book a home blood draw for my child, and is it safe for neonates?
Our DHA‑licensed pediatric phlebotomists perform gentle, antiseptic venipuncture at your home between 8 AM and 11 PM, even for newborns, adhering to strict cold‑chain transport. The whole process takes less than 10 minutes, and we use a tiny butterfly needle designed for fragile veins. A legal guardian must be present to sign the consent.
3. Will my insurance cover this genetic test, and what if the result is unclear?
Direct billing verification via WhatsApp (+971 54 548 8731) confirms coverage with major UAE insurers; we also offer a 0% installment plan for self‑pay patients. Should a variant of uncertain significance (VUS) be detected, our clinical genetics team provides a free follow‑up consultation and, when indicated, family segregation analysis at no extra cost.
UAE Regulatory & Data Privacy Adherence
Our laboratory operates under the following UAE legal frameworks:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – all patient data is encrypted and handled with explicit consent.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – governs secure electronic health records and telemedicine.
- Federal Decree-Law No. 4 of 2016 on Medical Liability – ensures patient safety and informed consent for all clinical procedures.
Accreditation: ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139) and College of American Pathologists (CAP) Accredited Laboratory.
Clinical & Logistical Metadata
| Test Name | CHRND Gene Sequencing for Congenital Myasthenic Syndrome Type 3C |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole Blood (EDTA/ACD), Extracted DNA, or Dried Blood Spot (FTA Card) |
| Methodology Used | Next-Generation Sequencing (NGS) |
| ICD-10-CM Code | G70.2, Z15.09, Z13.79 |
| LOINC Code | 86635-0 |
| DHA Facility License & Laboratory Address | DHA Facility License #1143 Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians